KOL Insight – Psoriatic Arthritis (Recent Trends, June 2026)

KOLs affirm TNF inhibitors remain a cornerstone of PsA therapy, especially in patients with axial involvement or high inflammatory burden, even as newer IL‑17 and IL‑23 inhibitors gain favor in patients with prominent skin and ocular disease.

Global market intelligence and KOL interviews highlight growing preference for IL‑17 (e.g., bimekizumab, ixekizumab) and IL‑23 inhibitors (e.g., risankizumab/SkyRizi, guselkumab/Tremfya) due to strong skin efficacy, infrequent dosing, and favorable safety profiles.

KOLs view the first‑in‑class TYK2 inhibitor deucravacitinib (Sotyktu) as a promising oral option for moderate PsA, appreciating its dual skin–joint benefit and oral administration, though some remain cautious pending longer‑term safety and real‑world data.

Multidisciplinary care and early screening by dermatologists and primary care are increasingly emphasized in KOL‑driven management frameworks, with structured screening every 6–12 months for psoriasis patients and explicit referral pathways to rheumatology.

KOLs stress that treatment decisions are increasingly individualized, balancing disease phenotype (skin‑versus‑joint‑dominant, axial vs peripheral), comorbidities, route of administration preference, payer and access constraints, and the evolving biosimilar landscape.